4.5 Article

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE 2014 ADVANCED FRAMEWORK FOR A NEW DIAGNOSIS OF OBESITY AS A CHRONIC DISEASE

Journal

ENDOCRINE PRACTICE
Volume 20, Issue 9, Pages 977-989

Publisher

AMER ASSOC CLINICAL ENDOCRINOLOGISTS
DOI: 10.4158/EP14280.PS

Keywords

-

Funding

  1. Astra Zeneca
  2. Merck Co., Inc.
  3. Weight Watchers International, Inc.
  4. Sanofi US
  5. Eisai Inc.
  6. Novo Nordisk
  7. AstraZeneca
  8. Boehringer Ingelheim GmbH
  9. MannKind Corporation
  10. Takeda Pharmaceutical Company Limited
  11. Eli Lilly and Company
  12. Janssen Pharmaceuticals, Inc.
  13. Bristol - Myers Squibb Company
  14. GlaxoSmithKline
  15. Amgen Inc.
  16. Gilead
  17. Intarcia Therapeutics, Inc.
  18. Lexicon Pharmaceuticals, Inc.
  19. Charles E. Schmidt College of Medicine at Florida Atlantic University (FAU)
  20. Bayer AG
  21. British Heart Foundation
  22. Cadila Pharmaceuticals Limited.
  23. Canadian Institutes of Health
  24. Wellcome Trust
  25. U.S. Food and Drug Administration
  26. National Institutes of Health
  27. UpToDate, Inc.
  28. Stryker Corporation
  29. Novartis AG

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available